Previous Section
Drug Therapy
1. Is lenalidomide a new standard treatment for myelodysplastic syndrome?
- Author
- Kuendgen A;
- Institution
- A Kuendgen is a Clinician and Researcher in the Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Dusseldorf, Germany.
- Journal
- Nat Clin Pract Oncol. 2007 May 15;.
2. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
- Author
- Knipp S; Hildebrand B; Kundgen A; Giagounidis A; Kobbe G; Haas R; Aul C; Gattermann N; Germing U;
- Institution
- Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine University, Dusseldorf, Germany. sabineknipp@hotmail.com
- Journal
- Cancer. 2007 Jul 15;110(2):345-52.
- Abstract URL
- Click here to view abstract
3. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
- Author
- Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E; Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E;
- Institution
- Journal
- Br J Haematol. 2007 Aug;138(4):555-7. Epub 2007 Jun 25.
4. The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
- Author
- Armand JP; Burnett AK; Drach J; Harousseau JL; Lowenberg B; San Miguel J; Armand JP; Burnett AK; Drach J; Harousseau JL; Lowenberg B; San Miguel J;
- Institution
- Institut Gustave-Roussy, Dept. of Medicine, 39 Rue Camille-Desmoulins, Villejuif Cedex 94805, France. armand.jean-pierre@claudiusregaud.fr
- Journal
- Oncologist. 2007 Mar;12(3):281-90.
- Abstract URL
- Click here to view abstract
5. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
- Author
- Kantarjian HM; O'Brien S; Huang X; Garcia-Manero G; Ravandi F; Cortes J; Shan J; Davisson J; Bueso-Ramos CE; Issa JP;
- Institution
- Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org
- Journal
- Cancer. 2007 Mar 15;109(6):1133-7.
- Abstract URL
- Click here to view abstract
6. Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000-4000 IU vitamin D(3)).
- Author
- Molnar I; Stark N; Lovato J; Powell BL; Cruz J; Hurd DD; Mathieu JS; Chen TC; Holick MF; Cambra S; McQuellon RP; Schwartz GG;
- Institution
- Journal
- Leukemia. 2007 May;21(5):1089-92. Epub 2007 Mar 8.
7. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.
- Author
- Porter J; Galanello R; Saglio G; Neufeld EJ; Vichinsky E; Cappellini MD; Olivieri N; Piga A; Cunningham MJ; Soulieres D; Gattermann N; Tchernia G; Maertens J; Giardina P; Kwiatkowski J; Quarta G; Jeng M; Forni GL; Stadler M; Cario H; Debusscher L; Della Porta M; Cazzola M; Greenberg P; Alimena G; Rabault B; Gathmann I; Ford JM; Alberti D; Rose C;
- Institution
- University College London, London, UK. j.porter@ucl.ac.uk
- Journal
- Eur J Haematol. 2008 Feb;80(2):168-76. Epub 2007 Nov 17.
- Abstract URL
- Click here to view abstract
8. Decitabine: in myelodysplastic syndromes.
- Author
- McKeage K; Croom KF;
- Institution
- Adis International Limited, 51 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand. demail@adis.co.nz
- Journal
- Drugs. 2006;66(7):951-8.
- Abstract URL
- Click here to view abstract
9. Treatment of myelodysplastic syndromes with exogenous erythropoietin: a new therapeutic paradigm.
- Author
- Mundle SD; Raza A;
- Institution
- Journal
- Leukemia. 2006 Sep;20(9):1481-3.
10. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
- Author
- Rzepecki P; Sarosiek T; Szczylik C; Rzepecki P; Sarosiek T; Szczylik C;
- Institution
- Department of Clinical Oncology, BMT Unit, Central Clinical Hospital Ministry of National Defence, 128 Szaserow Street, 00-909 Warsaw, Poland. piotr_rzepecki1@poczta.onet.pl
- Journal
- Jpn J Clin Oncol. 2006 Jan;36(1):46-9. Epub 2006 Jan 19.
- Abstract URL
- Click here to view abstract
Next: Clinical Trials
